Enhancing Rehabilitation After Stroke (Enhance)
Primary Purpose
Ischemic Stroke
Status
Unknown status
Phase
Phase 3
Locations
United States
Study Type
Interventional
Intervention
donepezil
placebo
Sponsored by
About this trial
This is an interventional treatment trial for Ischemic Stroke focused on measuring stroke, donepezil, recovery
Eligibility Criteria
Inclusion Criteria:
- male or female;
- aged 18 or older;
- new ischemic stroke within the preceding 30 days; and
- admitted to the an inpatient facility of the UPMC Institute for Rehabilitation and Research for post-stroke rehabilitation.
Exclusion Criteria:
- primary hemorrhagic stroke;
- current use of a cholinomimetic drug including tacrine, donepezil, galantamine, and rivastigmine;
- contraindication to AchEi therapy including bradycardia (< 50 bpm), severe asthma or COPD requiring nebulized medication, and active upper GI bleed or untreated gastric ulcer;
- myocardial infarction, poorly controlled congestive heart failure, or coronary bypass surgery within the last 3 months;
- current required use of an anticholinergic medication (e.g., for bladder spasm);
- current aphasia severe enough to prevent valid neuropsychiatric assessment (e.g., a score < 9 on the Token Test, part I and a score of < 14 (or <80% accuracy) on the repetition task of the Boston Diagnostic Aphasia Examination);
- current Major Depressive Episode AND HRSD > 20;
- current active suicidal ideation, plan, or intent;
- current mania or hypomania;
- current psychosis;
- meeting DMS-IV TR alcohol or substance abuse or dependence criteria within the preceding 3 months;
- subject and/or family informant do not speak English;
- history of a progressive or unstable CNS disease (e.g., multiple sclerosis, Parkinson's disease, HIV with CNS involvement);
- medically unstable (determined by review of the subject's medical status with the treating (clinical) physician and by review of standard blood tests); and
- history of sensitivity to donepezil;
- for potential subjects without a pacemaker or implantable defibrillator, exclusion criteria will include (a) ECG evidence of second or third degree heart block ( b ) ECG evidence of a tri-fascicular block (LBBB and 1st degree AV Block; RBBB, left anterior or left posterior hemiblock, and 1st degree AV block) or ( c ) history of syncope within 1 year with a RBBB or a LBBB.
- For females of child-bearing age, current pregnancy, plan to become pregnant while on study drug, or refusal to avoid pregnancy while on study drug.
- For females of child-bearing age, current breast feeding.
- suicidal attempt in the past one year,
- an inpatient admission for depression in the past one year
Sites / Locations
- Hillside Rehabilitation Hospital
- University of Pittsburgh Medical CenterRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
1: donepezil
2. placebo
Arm Description
Participants will receive treatment for 12 weeks on donepezil 10 mg (or 5 mg if unable to tolerate 10 mg). Treatment will be then be terminated and participants followed for another 12 weeks naturalistically.
Participants will receive treatment for 12 weeks with placebo pill. Treatment will be then be terminated and participants followed for another 12 weeks naturalistically.
Outcomes
Primary Outcome Measures
Functional Independence Measure (FIM)
Secondary Outcome Measures
Cognitive Function (ImPACT battery used to assess attention - working memory continuum, information processing speed, and verbal and visual episodic memory.)
Full Information
NCT ID
NCT00868010
First Posted
March 22, 2009
Last Updated
March 4, 2013
Sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
1. Study Identification
Unique Protocol Identification Number
NCT00868010
Brief Title
Enhancing Rehabilitation After Stroke
Acronym
Enhance
Official Title
Donepezil to Promote Functional Recovery Post-stroke
Study Type
Interventional
2. Study Status
Record Verification Date
March 2013
Overall Recruitment Status
Unknown status
Study Start Date
March 2009 (undefined)
Primary Completion Date
August 2013 (Anticipated)
Study Completion Date
November 2013 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
This is a 12-week, randomized, placebo controlled study to determine if donepezil (Aricept) treatment during rehabilitation after stroke improves functional recovery.
Detailed Description
Stroke is a leading cause of disability in the US (Thom 2006). The total number of stroke survivors (currently estimated as 5.5 million Americans) will continue to increase as the population ages and as the medical management of acute stroke continues to improve. Given stroke's devastating impact on activities of daily living and the large numbers of Americans afflicted, improving acute medical rehabilitation outcomes after stroke is of great public health importance.
Predictors of poor functional recovery post-stroke include impairments in cognition and motivation. Recent evidence indicates that acetylcholinesterase inhibitors may improve cognition and motivation; hence, their use post-stroke may lead to improved rehabilitation outcomes. Our group has demonstrated that use of the acetylcholinesterase inhibitor donepezil is associated with improved functional recovery in a pilot sample (n = 40) of elderly, cognitively impaired stroke survivors undergoing inpatient rehabilitation. Specifically, in this 12 week open-label study, those subjects receiving donepezil experienced a clinically meaningful 14 point greater improvement on the Functional Independence Measure (FIM) than an archival comparator group.
Based on these promising pilot study results, we propose a 12-week randomized, double-blind, placebo-controlled trial (followed by a 12 week off-drug observation period) in order to test the efficacy of donepezil to promote post-stroke functional recovery in older, cognitively impaired stroke survivors undergoing inpatient rehabilitation. We will also use this randomized controlled trial to examine the drug's effect on cognition post-stroke; specifically, the drug's effect on those cognitive domains (attention/working memory, information psychomotor speed, and episodic memory) that are relevant to functional outcomes.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Ischemic Stroke
Keywords
stroke, donepezil, recovery
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
200 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
1: donepezil
Arm Type
Experimental
Arm Description
Participants will receive treatment for 12 weeks on donepezil 10 mg (or 5 mg if unable to tolerate 10 mg). Treatment will be then be terminated and participants followed for another 12 weeks naturalistically.
Arm Title
2. placebo
Arm Type
Placebo Comparator
Arm Description
Participants will receive treatment for 12 weeks with placebo pill. Treatment will be then be terminated and participants followed for another 12 weeks naturalistically.
Intervention Type
Drug
Intervention Name(s)
donepezil
Other Intervention Name(s)
Aricept
Intervention Description
5 mg or 10 mg, titrated per drug insert. Participants may remain in the study at 5 mg if unable to tolerate 10 mg.
Intervention Type
Drug
Intervention Name(s)
placebo
Intervention Description
Participants will receive a placebo pill for 12 weeks if randomized to this treatment.
Primary Outcome Measure Information:
Title
Functional Independence Measure (FIM)
Time Frame
Weekly/12 weeks
Secondary Outcome Measure Information:
Title
Cognitive Function (ImPACT battery used to assess attention - working memory continuum, information processing speed, and verbal and visual episodic memory.)
Time Frame
Multiple time points over 12 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
male or female;
aged 18 or older;
new ischemic stroke within the preceding 30 days; and
admitted to the an inpatient facility of the UPMC Institute for Rehabilitation and Research for post-stroke rehabilitation.
Exclusion Criteria:
primary hemorrhagic stroke;
current use of a cholinomimetic drug including tacrine, donepezil, galantamine, and rivastigmine;
contraindication to AchEi therapy including bradycardia (< 50 bpm), severe asthma or COPD requiring nebulized medication, and active upper GI bleed or untreated gastric ulcer;
myocardial infarction, poorly controlled congestive heart failure, or coronary bypass surgery within the last 3 months;
current required use of an anticholinergic medication (e.g., for bladder spasm);
current aphasia severe enough to prevent valid neuropsychiatric assessment (e.g., a score < 9 on the Token Test, part I and a score of < 14 (or <80% accuracy) on the repetition task of the Boston Diagnostic Aphasia Examination);
current Major Depressive Episode AND HRSD > 20;
current active suicidal ideation, plan, or intent;
current mania or hypomania;
current psychosis;
meeting DMS-IV TR alcohol or substance abuse or dependence criteria within the preceding 3 months;
subject and/or family informant do not speak English;
history of a progressive or unstable CNS disease (e.g., multiple sclerosis, Parkinson's disease, HIV with CNS involvement);
medically unstable (determined by review of the subject's medical status with the treating (clinical) physician and by review of standard blood tests); and
history of sensitivity to donepezil;
for potential subjects without a pacemaker or implantable defibrillator, exclusion criteria will include (a) ECG evidence of second or third degree heart block ( b ) ECG evidence of a tri-fascicular block (LBBB and 1st degree AV Block; RBBB, left anterior or left posterior hemiblock, and 1st degree AV block) or ( c ) history of syncope within 1 year with a RBBB or a LBBB.
For females of child-bearing age, current pregnancy, plan to become pregnant while on study drug, or refusal to avoid pregnancy while on study drug.
For females of child-bearing age, current breast feeding.
suicidal attempt in the past one year,
an inpatient admission for depression in the past one year
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Kara Kenton
Phone
412-246-5815
Email
kentonkd@upmc.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ellen M Whyte, MD
Organizational Affiliation
University of Pittsburgh
Official's Role
Principal Investigator
Facility Information:
Facility Name
Hillside Rehabilitation Hospital
City
Warren
State/Province
Ohio
ZIP/Postal Code
44484
Country
United States
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Nancy Landgraff, PhD
Phone
330-941-2703
Email
nlandgra@cc.ysu.edu
First Name & Middle Initial & Last Name & Degree
Nancy Landgraff, PhD
Facility Name
University of Pittsburgh Medical Center
City
Pittsburgh
State/Province
Pennsylvania
ZIP/Postal Code
15213
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Kara Kenton
Phone
412-246-5815
Email
kentonkd@upmc.edu
First Name & Middle Initial & Last Name & Degree
Howard Aizenstein, MD, PhD
First Name & Middle Initial & Last Name & Degree
Ellen M Whyte, MD
First Name & Middle Initial & Last Name & Degree
Meryl Butters, PhD
First Name & Middle Initial & Last Name & Degree
Ariel Gildengers, MD
First Name & Middle Initial & Last Name & Degree
Jordan Karp, MD
First Name & Middle Initial & Last Name & Degree
Oscar Lopez, MD
First Name & Middle Initial & Last Name & Degree
Sati Mazumdar, MD
First Name & Middle Initial & Last Name & Degree
Michael Munin, MD
First Name & Middle Initial & Last Name & Degree
Charles Reynolds, MD
First Name & Middle Initial & Last Name & Degree
Elizabeth Skidmore, PhD
12. IPD Sharing Statement
Citations:
Citation
Thom T, Haase N, Rosamond W, Howard VJ, Rumsfeld J, Manolio T, Zheng ZJ, Flegal K, O'Donnell C, Kittner S, Lloyd JD, Goff DC, Hong Y, (2006): Heart Disease and Stroke Statistics-2006 Update, American Heart Association: February 14, 2006. http://circ.ahajournals.org/cgi/reprint/CIRCULATIONAHA.105.171600v1
Results Reference
background
PubMed Identifier
18667813
Citation
Whyte EM, Lenze EJ, Butters M, Skidmore E, Koenig K, Dew MA, Penrod L, Mulsant BH, Pollock BG, Cabacungan L, Reynolds CF 3rd, Munin MC. An open-label pilot study of acetylcholinesterase inhibitors to promote functional recovery in elderly cognitively impaired stroke patients. Cerebrovasc Dis. 2008;26(3):317-21. doi: 10.1159/000149580. Epub 2008 Jul 31.
Results Reference
background
Links:
URL
http://www.strokeassociation.org
Description
American Stroke Association website provides general information regarding stroke and stroke prevention.
Learn more about this trial
Enhancing Rehabilitation After Stroke
We'll reach out to this number within 24 hrs